Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omeprazole + amoxicillin + metronidazole (University of Tabriz)
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy, consisting of the proton pump inhibitor omeprazole and the antibiotics amoxicillin and metronidazole, is being investigated by Tabriz University for the treatment of idiopathic central serous chorioretinopathy (ICSCR). The therapeutic rationale is based on the hypothesis that *Helicobacter pylori* infection may play a role in the pathogenesis of ICSCR through immunologic or infectious processes. Omeprazole acts to reduce gastric acid secretion, which enhances the stability and efficacy of the co-administered antibiotics. Amoxicillin and metronidazole work synergistically to eradicate *H. pylori* infection. The clinical objective is to determine if the eradication of this bacterium promotes the resorption of subretinal fluid and leads to disease remission in patients with ICSCR.
- Other names
- H. pylori eradication therapyTriple therapyomeprazole-Tabriz University-central serous chorioretinopathy
02
Targets
NeuraminidasePBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on omeprazole + amoxicillin + metronidazole (University of Tabriz).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omeprazole + amoxicillin + metronidazole (University of Tabriz).